Inj, clindamycin phosp 300mg
Products billed under this code include Cleocin, Clindamycin Phosphate.
Payment limit per 300 MG, by effective quarter, 3Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J0736
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cleocin | Pfizer Inc | 00009-0728-09 | 150 | $278.10 |
| Cleocin | Pfizer Inc | 00009-0775-26 | 50 | $92.70 |
| Cleocin | Pfizer Inc | 00009-0870-26 | 25 | $46.35 |
| Cleocin | Pfizer Inc | 00009-0902-18 | 75 | $139.05 |
| Cleocin | Pfizer Inc | 00009-3051-02 | 25 | $46.35 |
| Cleocin | Pfizer Inc | 00009-4073-04 | 50 | $92.70 |
| Cleocin | Pfizer Inc | 00009-5095-06 | 75 | $139.05 |
| Cleocin | Henry Schein Inc. | 00404-9837-02 | 1 | $1.854 |
| Clindamycin Phosphate | Hikma Pharmaceuticals USA Inc. | 00143-9267-01 | 1 | $1.854 |
| Clindamycin Phosphate | Hikma Pharmaceuticals USA Inc. | 00143-9268-01 | 2 | $3.708 |
Show all 27 products
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Clindamycin Phosphate | Hikma Pharmaceuticals USA Inc. | 00143-9269-01 | 3 | $5.562 |
| Clindamycin Phosphate | Baxter Healthcare Corporation | 00338-3410-24 | 24 | $44.496 |
| Clindamycin Phosphate | Baxter Healthcare Corporation | 00338-3612-24 | 48 | $88.992 |
| Clindamycin Phosphate | Baxter Healthcare Corporation | 00338-3616-24 | 48 | $88.992 |
| Clindamycin Phosphate | Baxter Healthcare Corporation | 00338-3814-24 | 72 | $133.488 |
| Clindamycin Phosphate | Baxter Healthcare Corporation | 00338-4114-24 | 72 | $133.488 |
| Clindamycin Phosphate | Henry Schein Inc. | 00404-9838-04 | 2 | $3.708 |
| Clindamycin Phosphate | Sandoz Inc. | 00781-3288-09 | 24 | $44.496 |
| Clindamycin Phosphate | Sandoz Inc. | 00781-3289-09 | 48 | $88.992 |
| Clindamycin Phosphate | Sandoz Inc. | 00781-3290-09 | 72 | $133.488 |
| Clindamycin Phosphate | Sagent Pharmaceuticals | 25021-0115-02 | 25 | $46.35 |
| Clindamycin Phosphate | Sagent Pharmaceuticals | 25021-0115-04 | 50 | $92.70 |
| Clindamycin Phosphate | Sagent Pharmaceuticals | 25021-0115-06 | 75 | $139.05 |
| Clindamycin Phosphate | Baxter Healthcare Corporation | 43066-0993-24 | 48 | $88.992 |
| Clindamycin Phosphate | Baxter Healthcare Corporation | 43066-0995-24 | 72 | $133.488 |
| Clindamycin Phosphate | Civica, Inc. | 72572-0074-24 | 48 | $88.992 |
| Clindamycin Phosphate | Civica, Inc. | 72572-0076-24 | 72 | $133.488 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $1.854 | −$0.12 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted September 17, 2026 |
| 3Q26 | $1.974 | +$0.119 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted September 15, 2026 |
| 2Q26 | $1.855 | −$0.058 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted September 15, 2026 |
| 1Q26 | $1.913 | +$0.085 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted September 15, 2026 |
| 4Q25 | $1.828 | +$0.157 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted September 8, 2026 |
| 3Q25 | $1.671 | +$0.058 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted March 10, 2026 |
| 2Q25 | $1.613 | −$0.521 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted March 10, 2026 |
| 1Q25 | $2.134 | −$0.331 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted December 19, 2025 |
| 4Q24 | $2.465 | +$0.074 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted June 11, 2025 |
| 3Q24 | $2.391 | +$0.125 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted June 11, 2025 |
| 2Q24 | $2.266 | +$0.362 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted March 11, 2025 |
| 1Q24 | $1.904 | −$0.111 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted December 19, 2024 |
| 4Q23 | $2.015 | +$0.409 | 300 MG | Inj, clindamycin phosp 300mg | v1, posted October 10, 2024 |
| 3Q23 | $1.606 | – | 300 MG | Inj, clindamycin phosp 300mg | v1, posted June 5, 2024 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 2Q26: 2026-09-15_april-2026-medicare-part-b-payment-limit-files-final-file.zipposted September 15, 2026
- 1Q26: 2026-09-15_january-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 4Q25: 2026-09-08_october-2025-asp-pricing-final-file.zipposted September 8, 2026
- 3Q25: 2026-03-10_july-2025-asp-pricing-file.zipposted March 10, 2026
- 2Q25: 2026-03-10_april-2025-asp-pricing-file.zipposted March 10, 2026
- 1Q25: 2025-12-19_january-2025-asp-pricing-file-03-11-25-final-file.zipposted December 19, 2025
- 4Q24: 2025-06-11_october-2024-asp-pricing-file.zipposted June 11, 2025
- 3Q24: 2025-06-11_july-2024-asp-pricing-file.zipposted June 11, 2025
- 2Q24: 2025-03-11_april-2024-asp-pricing-file.zipposted March 11, 2025
- 1Q24: 2024-12-19_january-2024-asp-pricing-file.zipposted December 19, 2024
- 4Q23: 2024-10-10_october-2023-asp-pricing-file.zipposted October 10, 2024
- 3Q23: 2024-06-05_july-2023-asp-pricing-file.zipposted June 5, 2024